Find Relugolix manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 737789-87-6, Tak-385, Orgovyx, Tak 385, 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea, Chembl1800159
Molecular Formula
C29H27F2N7O5S
Molecular Weight
623.6  g/mol
InChI Key
AOMXMOCNKJTRQP-UHFFFAOYSA-N
FDA UNII
P76B05O5V6

Relugolix
Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.
Relugolix is a Gonadotropin Releasing Hormone Receptor Antagonist. The mechanism of action of relugolix is as a Gonadotropin Releasing Hormone Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of relugolix is by means of Decreased GnRH Secretion.
1 2D Structure

Relugolix

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
2.1.2 InChI
InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)
2.1.3 InChI Key
AOMXMOCNKJTRQP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
2.2 Other Identifiers
2.2.1 UNII
P76B05O5V6
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea

2. Orgovyx

3. Tak 385

4. Tak-385

5. Tak385

2.3.2 Depositor-Supplied Synonyms

1. 737789-87-6

2. Tak-385

3. Orgovyx

4. Tak 385

5. 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea

6. Chembl1800159

7. P76b05o5v6

8. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea

9. Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-n'-methoxy-

10. Relugolix [usan:inn]

11. Unii-p76b05o5v6

12. Tak385

13. Tak-385/tak385

14. Relugolix (jan/inn)

15. Relugolix [inn]

16. Relugolix [jan]

17. Relugolix(tak-385)

18. Relugolix [usan]

19. Relugolix [who-dd]

20. Schembl778416

21. Gtpl5586

22. Relugolix [orange Book]

23. C29h27f2n7o5s

24. Dtxsid40224167

25. Rvt-601

26. Amy27916

27. Bcp21587

28. Ex-a1083

29. Myfembree Component Relugolix

30. Tak-385; Rvt-601

31. Bdbm50347982

32. Mfcd25976856

33. S5808

34. Zinc43206033

35. Cs-5917

36. Db11853

37. Relugolix Component Of Myfembree

38. Sb16721

39. Ac-35863

40. Bs-18032

41. Hy-16474

42. N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-n'-methoxyurea

43. D10888

44. A857822

45. Ryeqo (relugolix-estradiol-norethisterone Acetate)

46. Q21099000

47. 1-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea

48. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[4,5-e]pyrimidin-6-yl]phenyl]-3-methoxyurea

49. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea;relugolix

50. 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 623.6 g/mol
Molecular Formula C29H27F2N7O5S
XLogP33.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count11
Rotatable Bond Count9
Exact Mass623.17624448 g/mol
Monoisotopic Mass623.17624448 g/mol
Topological Polar Surface Area158 Ų
Heavy Atom Count44
Formal Charge0
Complexity1010
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Relugolix is indicated for the treatment of adult patients with advanced prostate cancer. In a combination product with [estradiol] and [norethindrone], relugolix is indicated for the once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.


Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer .


5 Pharmacology and Biochemistry
5.1 Pharmacology

Approximately 56% of patients achieved castrate-level testosterone concentrations (<50 ng/dL) by day 4 of therapy and 97% of patients maintain these levels through 48 weeks of therapy. Relugolix requires once-daily oral administration to maintain the desired testosterone concentrations. Androgen deprivation therapies may prolong the QTc interval and should therefore be used with caution in patients having a high baseline risk of QTc prolongation, such as those with electrolyte abnormalities, congestive heart failure, or using other medications known to prolong the QTc interval. Based on its mechanism of action and data from animal studies, relugolix may result in fetal harm if administered to pregnant females - male patients with female partners should be advised to use effective contraception throughout therapy and for 2 weeks following cessation of therapy to prevent inadvertent fetal exposure.


5.2 MeSH Pharmacological Classification

Androgen Antagonists

Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
RELUGOLIX
5.3.2 FDA UNII
P76B05O5V6
5.3.3 Pharmacological Classes
Cytochrome P450 2B6 Inducers [MoA]; Cytochrome P450 3A Inducers [MoA]; Decreased GnRH Secretion [PE]; Gonadotropin Releasing Hormone Receptor Antagonist [EPC]; Gonadotropin Releasing Hormone Receptor Antagonists [MoA]; P-Glycoprotein Inhibitors [MoA]; Breast Cancer Resistance Protein Inhibitors [MoA]
5.4 ATC Code

L02BX


L - Antineoplastic and immunomodulating agents

L02 - Endocrine therapy

L02B - Hormone antagonists and related agents

L02BX - Other hormone antagonists and related agents

L02BX04 - Relugolix


5.5 Absorption, Distribution and Excretion

Absorption

The Cmax and AUC of orally-administered relugolix increase proportionally following single doses - in contrast, with repeat dosing the AUC remains proportional to the dose while the Cmax increases greater than proportionally to the dose. Following the administration of 120mg once daily, the steady-state AUC and Cmax of relugolix were 407 ( 168) ng.hr/mL and 70 ( 65) ng/mL, respectively. The absolute oral bioavailability of relugolix is approximately 12% and the median Tmax following oral administration is 2.25 hours.


Route of Elimination

Approximately 81% of an orally administered dose was recovered in the feces, of which 4.2% was unchanged parent drug, while 4.1% of the dose was recovered in the urine, of which 2.2% remained unchanged.


Clearance

The average renal clearance of relugolix is 8 L/h with a total clearance of 26.4 L/h.


5.6 Metabolism/Metabolites

Relugolix is metabolized mainly by the CYP3A subfamily of P450 enzymes, with a smaller contribution by CYP2C8.


5.7 Biological Half-Life

The average effective half-life of relugolix is 25 hours, while the average terminal elimination half-life is 60.8 hours.


5.8 Mechanism of Action

The pathogenesis and progression of prostate cancer appear driven, at least in part, by the effects of testosterone. Androgen deprivation has been demonstrated to result in cell death and tumor regression in many well-differentiated prostate cancer cell lines - for this reason, androgen deprivation therapy (ADT) has become a standard in the treatment of prostate cancer, particularly in advanced disease. Testosterone production in males is carried out in the Leydig cells of testes and is stimulated by luteinizing hormone (LH), which itself is produced in the pituitary gland following the binding of gonadotropin-releasing hormone (GnRH) to corresponding GnRH receptors. Relugolix is a competitive antagonist of these GnRH receptors, thereby decreasing the release of LH and, ultimately, testosterone.


API SUPPLIERS

read-more
read-more

01

Moehs Iberica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Moehs Iberica

02

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

03

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Dr Reddy Company Banner

04

Aptra Synthesis

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAptra Synthesis produces APIs, Pellets (Semi-finished Formulations), and Intermediates.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Aptra Synthesis

05

Medichem S.A

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMedichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Medichem

06

Shandong Loncom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Loncom Pharmaceutical company banner

07

Farmhispania

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFarmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Farmhispania

08

Porton Pharma Solutions

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Porton Company Banner

09

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

10

Lee Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Lee Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652207400,"product":"RELUGOLIX API","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"YILING WANYANG IMPORT AND EXPORT CO., LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"5.80","actualQuantity":"5.8","unit":"KGS","unitRateFc":"8000","totalValueFC":"46258.5","currency":"USD","unitRateINR":"616400","date":"11-May-2022","totalValueINR":"3575120","totalValueInUsd":"46258.5","indian_port":"HYDERABAD AIR","hs_no":"29051990","bill_no":"8639652","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652985000,"product":"RELUGOLIX AMINE COMPOUND(QTY:500GMS, VALUE:USD 5800)","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DFM INTERNATIONAL LIMITED","supplierCountry":"CHINA","foreign_port":"NA","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"11600","totalValueFC":"5898.6","currency":"USD","unitRateINR":"911760","date":"20-May-2022","totalValueINR":"455880","totalValueInUsd":"5898.6","indian_port":"HYDERABAD AIR","hs_no":"29333919","bill_no":"8755204","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669573800,"product":"RELUGOLIX API","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DFM INTERNATIONAL LIMITED","supplierCountry":"CHINA","foreign_port":"NA","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"7725","totalValueFC":"195490.7","currency":"USD","unitRateINR":"638180.7","date":"28-Nov-2022","totalValueINR":"15954517.82","totalValueInUsd":"195490.7","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"3508675","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1672079400,"product":"RELUGOLIX","address":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST","city":"MUMBAI,MAHARASHTRA","supplier":"AURISCO PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"NA","customer":"NOVARTIS PHARMACEUTICALS CORPORATION","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"12000","totalValueFC":"12166.6","currency":"USD","unitRateINR":"1002600","date":"27-Dec-2022","totalValueINR":"1002600","totalValueInUsd":"12166.6","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"3923976","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674844200,"product":"RELUGOLIX","address":"12TH FLOOR, COMMERZ II,,INTERNATIO NAL BUSNESS PARK,OBEROI","city":"GARDEN CITY OFF WESTERN EXPR HIGHWA","supplier":"PLUSCHEM","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"TEVA PHARMACEUTICAL INDUSTRIES","customerCountry":"INDIA","quantity":"0.43","actualQuantity":"0.425","unit":"KGS","unitRateFc":"19000","totalValueFC":"9754.1","currency":"USD","unitRateINR":"1876440","date":"28-Jan-2023","totalValueINR":"797487","totalValueInUsd":"9754.1","indian_port":"BOMBAY AIR","hs_no":"29333990","bill_no":"4383978","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"12TH FLOOR, COMMERZ II,,INTERNATIO NAL BUSNESS PARK,OBEROI"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677090600,"product":"RELUGOLIX","address":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST","city":"MUMBAI,MAHARASHTRA","supplier":"AURISCO PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"NA","customer":"NOVARTIS PHARMACEUTICALS CORPORATION","customerCountry":"INDIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"12000","totalValueFC":"36462","currency":"USD","unitRateINR":"1003800","date":"23-Feb-2023","totalValueINR":"3011400","totalValueInUsd":"36462","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"4770524","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1681065000,"product":"INTERMEDIATES - RELUGOLIX INTERMEDIATE","address":"SCO 915, 2ND FLOOR,,NAC, MANIMAJRA ,","city":"CHANDIGARH,CHANDIGARH","supplier":"HANGZHOU LONGSHINE BIO-TECH","supplierCountry":"CHINA","foreign_port":"NA","customer":"ADLEY LAB LIMITED","customerCountry":"INDIA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"14250","totalValueFC":"2881.2","currency":"USD","unitRateINR":"1180612.5","date":"10-Apr-2023","totalValueINR":"236122.5","totalValueInUsd":"2881.2","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"5455311","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SCO 915, 2ND FLOOR,,NAC, MANIMAJRA ,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1681756200,"product":"(FOC) RELUGOLIX (1 PACK X 22 KG =22 KG) (DSIR NO TU\/IV-RD\/2638\/2020 DT 28\/08\/2020)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"INTAS PHARMACEUTICALS","supplierCountry":"GERMANY","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"22.00","actualQuantity":"22","unit":"KGS","unitRateFc":"5000","totalValueFC":"117957.1","currency":"USD","unitRateINR":"439410.4","date":"18-Apr-2023","totalValueINR":"9667028.13","totalValueInUsd":"117957.1","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"5569236","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695580200,"product":"RELUGOLIX (FOC) (R & D PURPOSE ONLY)","address":"2ND FLOOR, CHINUBHAI CENTRE,","city":"AHMEDABAD, GUJARAT","supplier":"INTAS PHARMACEUTICALS","supplierCountry":"GERMANY","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"5000","totalValueFC":"7958.4","currency":"USD","unitRateINR":"440409.5","date":"25-Sep-2023","totalValueINR":"660614.21","totalValueInUsd":"7958.4","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"7996013","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"FRANKFURT\/MAIN INT\\'L","supplierAddress":"SAGE HOUSE, 319 PINNER ROAD NORTH HARROW, HA1 4HFSDNF UNITED KINGDOM","customerAddress":"2ND FLOOR, CHINUBHAI CENTRE,"}]
11-May-2022
25-Sep-2023
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 12, 2024

blank

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.

Brand Name : Orgovyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 12, 2024

blank

Details:

Rexigo (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in India for testosterone suppression in patients with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Rexigo

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 01, 2024

blank

02

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Rexigo (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in India for testosterone suppression in patients with advanced prostate cancer.

Brand Name : Rexigo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 01, 2024

blank

Details:

Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.


Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Ryeqo

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2023

blank

03

Gedeon Richter

Hungary
arrow
BIO Partnering at JPM
Not Confirmed

Gedeon Richter

Hungary
arrow
BIO Partnering at JPM
Not Confirmed

Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Brand Name : Ryeqo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 02, 2023

blank

Details:

ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 24, 2023

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.

Brand Name : Orgovyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 24, 2023

blank

Details:

Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 23, 2023

blank

05

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.

Brand Name : Orgovyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 23, 2023

blank

Details:

Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.


Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Myfembree

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Pfizer Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 19, 2023

blank

06

Sumitomo

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Sumitomo

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Details : Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.

Brand Name : Myfembree

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 19, 2023

blank

Details:

Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.


Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Ryeqo

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Sumitomo

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 15, 2023

blank

07

Gedeon Richter

Hungary
arrow
BIO Partnering at JPM
Not Confirmed

Gedeon Richter

Hungary
arrow
BIO Partnering at JPM
Not Confirmed

Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Brand Name : Ryeqo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 15, 2023

blank

Details:

Sumitovant and Myovant will strengthen Myovant's two products, Orgovyx® (relugolix) and Myfembree® capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Sumitovant Biopharma

Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million

Deal Type: Acquisition March 10, 2023

blank

08

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Sumitovant and Myovant will strengthen Myovant's two products, Orgovyx® (relugolix) and Myfembree® capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health.

Brand Name : Orgovyx

Molecule Type : Small molecule

Upfront Cash : $1,700.0 million

March 10, 2023

blank

Details:

Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 20, 2022

blank

09

Clinigen Group

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

Clinigen Group

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

Details : Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Brand Name : Orgovyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 20, 2022

blank

Details:

Sumitovant and Myovant will strengthen Myovant's two products, Orgovyx® (relugolix) and Myfembree® capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Sumitovant Biopharma

Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million

Deal Type: Acquisition October 23, 2022

blank

10

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Sumitovant and Myovant will strengthen Myovant's two products, Orgovyx® (relugolix) and Myfembree® capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health.

Brand Name : Orgovyx

Molecule Type : Small molecule

Upfront Cash : $1,700.0 million

October 23, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

CAS Number : 308831-95-0

End Use API : Relugolix

About The Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, c...

Aarti Industries Company Banner

02

BIO Partnering at JPM
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

CAS Number : 1589503-95-6

End Use API : Relugolix

About The Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, c...

Aarti Industries Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Orgovyx

Relugolix

arrow
Biotech Showcase
Not Confirmed

Brand Name : Orgovyx

U.S.A
arrow
Biotech Showcase
Not Confirmed

Relugolix

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 51

2020 Revenue in Millions : 0

Growth (%) : 100

blank

02

Brand Name : Myfembree/Ryeqo

Relugolix

arrow
Biotech Showcase
Not Confirmed

Brand Name : Myfembree/Ryeqo

U.S.A
arrow
Biotech Showcase
Not Confirmed

Relugolix

Main Therapeutic Indication : Women's Healthcare

Currency : USD

2021 Revenue in Millions : 8

2020 Revenue in Millions : 0

Growth (%) : New Launch in 2021

blank

03

Brand Name : Orgovyx

Relugolix

arrow
Biotech Showcase
Not Confirmed

Brand Name : Orgovyx

U.S.A
arrow
Biotech Showcase
Not Confirmed

Relugolix

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 160

2021 Revenue in Millions : 51

Growth (%) : 216

blank

04

Brand Name : Myfembree/Ryeqo

Relugolix

arrow
Biotech Showcase
Not Confirmed

Brand Name : Myfembree/Ryeqo

U.S.A
arrow
Biotech Showcase
Not Confirmed

Relugolix

Main Therapeutic Indication : Women's Health

Currency : USD

2022 Revenue in Millions : 25

2021 Revenue in Millions : 8

Growth (%) : 234

blank

05

Brand Name : Orgovyx

Relugolix

arrow
Biotech Showcase
Not Confirmed

Brand Name : Orgovyx

U.S.A
arrow
Biotech Showcase
Not Confirmed

Relugolix

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 262

2022 Revenue in Millions : 160

Growth (%) : 86

blank

06

Brand Name : Myfembree/Ryeqo

Relugolix

arrow
Biotech Showcase
Not Confirmed

Brand Name : Myfembree/Ryeqo

U.S.A
arrow
Biotech Showcase
Not Confirmed

Relugolix

Main Therapeutic Indication : Women's Health

Currency : USD

2023 Revenue in Millions : 60

2022 Revenue in Millions : 32

Growth (%) : 110

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

RELUGOLIX

US Patent Number : 11583526

Drug Substance Claim :

Drug Product Claim :

Application Number : 214621

Patent Use Code : U-3020

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank

02

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

RELUGOLIX

US Patent Number : 11795178

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214621

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-09-27

blank

03

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

RELUGOLIX

US Patent Number : 8735401

Drug Substance Claim :

Drug Product Claim :

Application Number : 214621

Patent Use Code : U-3019

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2024-02-04

blank

04

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

RELUGOLIX

US Patent Number : 12144809

Drug Substance Claim :

Drug Product Claim :

Application Number : 214621

Patent Use Code : U-4035

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank

05

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

US Patent Number : 8058280

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 214846

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2025-01-28

blank

06

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

RELUGOLIX

US Patent Number : 7300935

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 214621

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2025-01-28

blank

07

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

RELUGOLIX

US Patent Number : 12097198

Drug Substance Claim :

Drug Product Claim :

Application Number : 214621

Patent Use Code : U-3020

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank

08

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

US Patent Number : 11957684

Drug Substance Claim :

Drug Product Claim :

Application Number : 214846

Patent Use Code : U-3129

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank

09

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

US Patent Number : 7300935

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 214846

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2025-01-28

blank

10

arrow
BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

US Patent Number : 11793812

Drug Substance Claim :

Drug Product Claim :

Application Number : 214846

Patent Use Code : U-2360

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-05-03

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Relugolix Manufacturers

A Relugolix manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Relugolix, including repackagers and relabelers. The FDA regulates Relugolix manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Relugolix API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Relugolix manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Relugolix Suppliers

A Relugolix supplier is an individual or a company that provides Relugolix active pharmaceutical ingredient (API) or Relugolix finished formulations upon request. The Relugolix suppliers may include Relugolix API manufacturers, exporters, distributors and traders.

click here to find a list of Relugolix suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Relugolix USDMF

A Relugolix DMF (Drug Master File) is a document detailing the whole manufacturing process of Relugolix active pharmaceutical ingredient (API) in detail. Different forms of Relugolix DMFs exist exist since differing nations have different regulations, such as Relugolix USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Relugolix DMF submitted to regulatory agencies in the US is known as a USDMF. Relugolix USDMF includes data on Relugolix's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Relugolix USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Relugolix suppliers with USDMF on PharmaCompass.

Relugolix NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Relugolix as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Relugolix API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Relugolix as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Relugolix and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Relugolix NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Relugolix suppliers with NDC on PharmaCompass.

Relugolix GMP

Relugolix Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Relugolix GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Relugolix GMP manufacturer or Relugolix GMP API supplier for your needs.

Relugolix CoA

A Relugolix CoA (Certificate of Analysis) is a formal document that attests to Relugolix's compliance with Relugolix specifications and serves as a tool for batch-level quality control.

Relugolix CoA mostly includes findings from lab analyses of a specific batch. For each Relugolix CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Relugolix may be tested according to a variety of international standards, such as European Pharmacopoeia (Relugolix EP), Relugolix JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Relugolix USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty